| Identification | Back Directory | [Name]
Mal-PEG8-acid | [CAS]
1818294-46-0 | [Synonyms]
Mal-PEG8-acid
Mal-PEG8-CH2CH2COOH
Maleimide-PEG8-CH2CH2COOH
4,7,10,13,16,19,22,25-Octaoxaheptacosanoic acid, 27-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)- | [Molecular Formula]
C23H39NO12 | [MDL Number]
MFCD26793771 | [MOL File]
1818294-46-0.mol | [Molecular Weight]
521.56 |
| Chemical Properties | Back Directory | [Boiling point ]
634.6±55.0 °C(Predicted) | [density ]
1.213±0.06 g/cm3(Predicted) | [solubility ]
Soluble in Water, DMSO, DCM, DMF | [form ]
powder | [pka]
4.28±0.10(Predicted) | [color ]
White | [InChI]
InChI=1S/C23H39NO12/c25-21-1-2-22(26)24(21)4-6-30-8-10-32-12-14-34-16-18-36-20-19-35-17-15-33-13-11-31-9-7-29-5-3-23(27)28/h1-2H,3-20H2,(H,27,28) | [InChIKey]
KLZPPWOSICDUKQ-UHFFFAOYSA-N | [SMILES]
C(O)(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCN1C(=O)C=CC1=O |
| Hazard Information | Back Directory | [Description]
Mal-PEG8-acid is a PEG linker containing a maleimide group with a terminal carboxylic acid. The hydrophilic PEG spacer increases solubility in aqueous media. The maleimide group will react with a thiol group to form a covalent bond, enabling the connection of biomolecule with a thiol. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. | [Uses]
Mal-PEG8-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. | [Application]
Mal-PEG8-acid is a key building block in the synthesis of antibody-drug conjugates for the treatment of cancer. The target molecule 7 is obtained in a single step by coupling the amino group of intermediate 40 to Mal-PEG8-acid following its in situ activation (with EDC·HCl) in solution. The PEG8 moiety in the structure provides the entire drug-linker with the necessary hydrophilicity and flexibility to improve solubility and pharmacokinetic properties. The terminal maleimide (mal) group is used for subsequent site-specific coupling with the thiol groups on the antibody, thereby forming the complete antibody-drug conjugate[1]. | [IC 50]
PEGs | [References]
[1] William R. F. Goundry*, & Bertrand Cottineau, (2024). Route Design and Scale-Up of a Topoisomerase I Inhibitor Antibody–Drug Conjugate Payload. Organic Process Research & Development, 28 6, 2355–2366. https://doi.org/10.1021/acs.oprd.4c00175 |
|
| Company Name: |
Biomatrik Inc. Gold
|
| Tel: |
0573-82623377 18967387295 |
| Website: |
www.biomatrik.cn |
|